Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
schizophrenia
MedTech
Meet Motivista: Click's new schizophrenia digital therapeutic
Click has nabbed FDA approval for its digital therapeutic Motivista, now the first authorized treatment for negative schizophrenia symptoms.
Ben Adams
Oct 5, 2026 6:00am
Teva saddles up as bidder for bankrupt BioXcel’s CNS assets
Aug 28, 2026 9:17am
MapLight turns off preclinical tap to fund schizophrenia drug
Aug 14, 2026 4:38am
MapLight shares sink on mixed ph. 2 schizophrenia readout
Jul 27, 2026 11:37am
FDA hits Newron schizophrenia ph. 3 trial with hold after death
Apr 29, 2026 2:50pm
Tortugas comes out of shell with $106M, 4 ph. 2-stage neuro meds
Apr 21, 2026 10:41am
